Overview
Scopolamine is an alkaloid, a secondary metabolite produced by plants of nightshade family such as henbane, Datura, Duboisia, etc. Scopolamine is used to treat motion sickness, and post-operative and anesthesia induced nausea and vomiting. It is often used to treat gastrointestinal spasm, irritable bowel syndrome and eye inflammation. Scopolamine is also used for nausea and vomiting prevention in chemotherapy for cancer treatment. Scopolamine can be administered orally as tablets or syrups, intravenously as injections and solutions, or as transdermal in form of patch or gel. Transdermal scopolamine is a scopolamine patch used to treat motion sickness and post-operative nausea and vomiting. Transdermal scopolamine available today are reservoir patches which can be used for up to 3 days. These patches are applied at back side of ear. These patches are applied 20 minutes to 4 hours before the intended use such as travel, surgery etc.
The first transdermal scopolamine patch was approved in 1979, manufactured by Alza Corporation and marketed by Novartis AG by brand name Transderm Scop. There are very few generics approved by FDA for Transderm Scop, which makes the market less competitive. Though there are few small players operating on regional level, however they hold a meager share in global transdermal scopolamine market. The global market for transdermal scopolamine is expected to grow at CAGR of 6.7% over the forecast period from 2016 to 2024. The launch of recently approved generics and projected expansion of international players is expected to drive the growth for this market. Moreover many of the industry players and researchers are investing on development of new transdermal scopolamine products.
Transdermal scopolamine is a preferred choice to treat motion sickness owing to its ease in administration, cost effectiveness and availability. Rise in number of travelers across globe is expected to drive the growth for transdermal scopolamine market over the forecast period. Moreover some of the industry players and researchers are investing on development of improved transdermal scopolamine patch on material, adhesion, drug bioavailability and other aspects. Expected introduction of such improved products coupled with launch of new entrants is expected to trigger the growth for transdermal scopolamine market. However there are few concern factors with transdermal scopolamine such as adverse effects, specifically the withdrawal symptoms which are anticipated to restrain growth.
Global Transdermal Scopolamine Market: Regional Outlook
Geographically, the transdermal scopolamine market has been segmented into five regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. These regions have been further segmented to country and sub-regional level. North America is expected to contribute largest share in global transdermal scopolamine market owing to high number of travelers, well established healthcare industry. Europe is expected to hold second position in global transdermal scopolamine market with growing number of surgeries and rising number of travelers.
The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global transdermal scopolamine market.
Companies Mentioned in the Report
The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Novartis AG, GlaxoSmithKline plc, Baxter International Inc., Perrigo Company plc, Caleb Pharmaceuticals, Inc., and Myungmoon Pharma Co. Ltd.
The global transdermal scopolamine market has been segmented as follows:
By Region
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2. Assumptions and Research Methodology
Chapter 3. Executive Summary: Global Transdermal Scopolamine Market
Chapter 4. Market Overview
4.1. Introduction
4.1.1. Scopolamine Indications
4.1.2. Industry Evolution / Developments
4.2. Market Overview
4.3. Key Market Indicators
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
4.5. Global Transdermal Scopolamine Market Analysis and Forecast, 2018 – 2026
4.5.1. Market Revenue Projections (US$ Mn)
4.6. Porter’s five forces analysis
4.7. Value Chain Analysis
4.8. Market Outlook
4.9. Global Company Share Analysis – 2018 (Estimated)
4.10. Scopolamine Product Prescription Rate by Region (%)
4.10.1. Oral
4.10.2. Injections
4.10.3. Transdermal / Patch
4.11. Pipeline Analysis – Transdermal Scopolamine
Chapter 5. Global Transdermal Scopolamine Market Analysis and Forecasts, By Region
5.1. Key Findings
5.2. Policies and Regulations
5.3. Market Size (US$ Mn) Forecast By Region
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. Latin America
5.3.5. Middle East and Africa
5.4. Market Attractiveness By Region
Chapter 6. North America Transdermal Scopolamine Market Analysis and Forecast
6.1. Introduction
6.1.1. Key Findings
6.1.2. Policies and Regulations
6.1.3. Price Trend Analysis
6.1.4. Key Trends
6.2. Market Size (US$ Mn) Forecast, By Country
6.2.1. U.S.
6.2.2. Canada
6.3. Market Attractiveness Analysis By Country
Chapter 7. Europe Transdermal Scopolamine Market Analysis and Forecast
7.1. Introduction
7.1.1. Key Findings
7.1.2. Policies and Regulations
7.1.3. Price Trend Analysis
7.1.4. Key Trends
7.2. Market Size (US$ Mn) Forecast, By Country
7.2.1. Germany
7.2.2. France
7.2.3. U.K.
7.2.4. Spain
7.2.5. Italy
7.2.6. Rest of Europe
7.3. Market Attractiveness Analysis By Country
Chapter 8. Asia Pacific Transdermal Scopolamine Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.1.2. Policies and Regulations
8.1.3. Price Trend Analysis
8.1.4. Key Trends
8.2. Market Size (US$ Mn) Forecast, By Country
8.2.1. Japan
8.2.2. China
8.2.3. India
8.2.4. Australia
8.2.5. Rest of Asia Pacific
8.3. Market Attractiveness Analysis By Country
Chapter 9. Latin America Transdermal Scopolamine Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Policies and Regulations
9.1.3. Price Trend Analysis
9.1.4. Key Trends
9.2. Market Size (US$ Mn) Forecast, By Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Market Attractiveness Analysis By Country
Chapter 10. Middle East & Africa Transdermal Scopolamine Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Policies and Regulations
10.1.3. Price Trend Analysis
10.1.4. Key Trends
10.2. Market Size (US$ Mn) Forecast, By Country
10.2.1. GCC Countries
10.2.2. South Africa
10.2.3. Rest of Middle East and Africa
10.3. Market Attractiveness Analysis By Country
Chapter 11. Competition Landscape
11.1. Transdermal Scopolamine Market – Competition Matrix (By Tier and Size of companies) (2015)
11.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
11.2.1. Baxter International Inc.
11.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
11.2.1.2. Product Portfolio
11.2.1.3. SWOT Analysis
11.2.1.4. Financial Overview
11.2.1.5. Strategic Overview
11.2.2. GlaxoSmithKline plc
11.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
11.2.2.2. Product Portfolio
11.2.2.3. SWOT Analysis
11.2.2.4. Financial Overview
11.2.2.5. Strategic Overview
11.2.3. Novartis AG
11.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
11.2.3.2. Product Portfolio
11.2.3.3. SWOT Analysis
11.2.3.4. Financial Overview
11.2.3.5. Strategic Overview
11.2.4. Perrigo Company plc.
11.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
11.2.4.2. Product Portfolio
11.2.4.3. SWOT Analysis
11.2.4.4. Financial Overview
11.2.4.5. Strategic Overview
11.2.5. Caleb Pharmaceuticals, Inc.
11.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
11.2.5.2. Product Portfolio
11.2.5.3. SWOT Analysis
11.2.5.4. Financial Overview
11.2.5.5. Strategic Overview
11.2.6. Myungmoon Pharma Co. LTD.
11.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
11.2.6.2. Product Portfolio
11.2.6.3. SWOT Analysis
11.2.6.4. Financial Overview
11.2.6.5. Strategic Overview
Chapter 12. Key Take Away
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers